Archive · 18 Nov 2025
Eli Lilly Approved for Alzheimer's Drug in India
Eli Lilly got permission to sell a new medicine in India that helps people with early signs of Alzheimer's disease.
This disease is the most common cause of memory loss problems, but many people in India don't know they have it yet.
The medicine works by slowing down the damage to the brain caused by the disease.
Eli Lilly and Company (India) received CDSCO approval for donanemab
Donanemab treats Alzheimer's disease in adults with early symptoms
Includes mild cognitive impairment and mild dementia stages
Drug targets amyloid plaques, slowing cognitive decline
Alzheimer's is the most common cause of dementia, underdiagnosed in India
- Who
- Eli Lilly and Company (India)
- What
- Received approval for donanemab to treat Alzheimer's disease
- When
- November 18, 2025
- Where
- India
- Why
- To treat Alzheimer's disease in adults with early symptoms
Pharmaceutical Companies
Healthcare Advocates
Drug Pricing
Pharmaceutical Companies
Pharmaceutical companies may prioritize profits, making drugs unaffordable for many patients.
Healthcare Advocates
Healthcare advocates argue for price controls to ensure accessibility for all patients.
- Drug Name
- Donanemab
- Dosage
- 350 mg/20 mL, every four weeks
- Administered
- Intravenous infusion
- Target
- Amyloid plaques in the brain
- Estimated Dementia Cases in India by 2030
- Over 8 million
